Rapid Exercise-Induced Mobilization of Dendritic Cells Is Potentially Mediated by a Flt3L- and MMP-9-Dependent Process in Multiple Sclerosis

Table 1

Clinical details of the study population.

	Controls	MS	P values
Gender (M/F)	4/5	10/12	0.960
Age ± SEM	46 ± 3	46 ± 2	0.960
BMI ± SEM	25 ± 1	24 ± 1	0.424
EDSS ± SEM	NA	3 ± 0.2	NA
Type MS (CP/RR)	NA	9/12	NA
Medication (untreated/1st-line treatment/2nd-line treatment)	NA	4/12/6	NA

Patients were defined as untreated when a wash-out period of at least 3 months was respected before recruitment in the study. 1st-line treatment: IFN-β (Avonex, Betaferon, and Rebif) and glatiramer acetate (Copaxone); 2nd-line treatment: alemtuzumab (Campath), natalizumab (Tysabri), and fingolimod (Gilenya). Results are shown as mean ± SEM. Missing data from one patient.
Abbreviations used are as follows: MS: multiple sclerosis; M: male; F: female; BMI: body mass index; EDSS: expanded disability status scale; CP: chronically progressive MS; RR: relapsing-remitting MS; SEM: standard error of the mean; NA: not applicable.